Clinical Trial

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

Study acronym: ENERGY
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-11
notable Primary completion moved earlier: 2027-11-11 -> 2026-10-14 2026-08-11
minor Completion moved earlier: 2027-11-11 -> 2026-10-14 2026-08-11
Trial Details
NCT Number NCT05734196
Lead Sponsor Inozyme Pharma
Collaborators: BioMarin Pharmaceutical
Conditions Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum
Enrollment 16 participants
Start Date 2023-06-25
Primary Completion 2026-10-14 (estimated)
Study Completion 2026-10-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-10